Novel insights into the effects of JMV2894, a growth hormone secretagogue, in Duchenne muscular dystrophy: A preclinical study in the D2-mdx mouse model
Open Access
- 13 November 2025
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 193, 118767
Abstract
No abstract availableKeywords
Funding Information
- AFM-Téléthon (PE0000006)
- Ministero dell'Università e della Ricerca
- French Muscular Dystrophy Association (22199)
This publication has 49 references indexed in Scilit:
- Circulating C1q levels in health and disease, more than just a biomarkerMolecular Immunology, 2021
- Proteome analysis in dystrophic mdx mouse muscle reveals a drastic alteration of key metabolic and contractile proteins after chronic exercise and the potential modulation by anti-oxidant compoundsJournal of Proteomics, 2018
- Unacylated Ghrelin Enhances Satellite Cell Function and Relieves the Dystrophic Phenotype in Duchenne Muscular Dystrophy mdx ModelStem Cells, 2017
- Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin‐induced cachexiaJournal of Cachexia, Sarcopenia and Muscle, 2017
- The Dystrophin Complex: Structure, Function, and Implications for TherapyComprehensive Physiology, 2015
- Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseasesPharmacology & Therapeutics, 2015
- LTBP4 genotype predicts age of ambulatory loss in duchenne muscular dystrophyAnnals of Neurology, 2012
- Effect of ghrelin and its analogues, BIM‐28131 and BIM‐28125, on the expression of myostatin in a rat heart failure modelJournal of Cachexia, Sarcopenia and Muscle, 2012
- The 1,2,4-triazole as a scaffold for the design of ghrelin receptor ligands: development of JMV 2959, a potent antagonistAmino Acids, 2012
- Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophyNeurobiology of Disease, 2008